On GLP-1 drugs, protein percentage holds while grams collapse
In short
During treatment with GLP-1 and dual GIP/GLP-1 receptor agonists, protein as a proportion of total energy was largely maintained in randomised liraglutide trials at roughly 13.9–17.5%. But because total energy intake falls, absolute protein in grams can drop, particularly with more potent appetite suppression. Even with the proportion preserved, absolute intake may fall below the level needed to adequately stimulate muscle protein synthesis in older adults.
People on weight-loss drugs often say their protein percentage is holding up. The data this review assembles shows that can be true and still not reassuring. In randomised liraglutide trials, protein held at roughly 13.9–17.5% of total energy. The problem is not the ratio — it is the denominator.
How can the percentage hold while intake falls short?
GLP-1 receptor agonists and dual GIP/GLP-1 agonists produce substantial weight loss by suppressing appetite and cutting calorie intake. When total energy falls, holding the same percentage still means absolute grams fall with it. Fifteen percent of 2,400 kcal is 90g; fifteen percent of 1,400 kcal is 52g.
The review notes this decline is more pronounced with more potent appetite suppression, and warns that once absolute intake drops it can land below the level required to adequately stimulate muscle protein synthesis.
Why is this worse with age?
Older adults carry anabolic resistance: the same dose of protein produces a weaker muscle protein synthesis response than it does in younger people. They start from a disadvantage at any given gram target, so a further drop in absolute intake pushes them back twice over.
Sarcopenia — the age-related decline in muscle mass and strength — raises the risk of falls, fractures, disability and mortality. Type 2 diabetes and obesity frequently coexist with it, producing sarcopenic obesity, a growing clinical challenge. These drugs are increasingly prescribed to older adults, which is exactly why the review raises the issue.
The review is explicit about its limits. Comprehensive dietary intake data remain scarce, and few studies have systematically evaluated whether these changes translate into clinically meaningful declines in muscle mass, strength or physical performance. Longer trials are needed.
So what should change?
- Set the protein target in grams per kilogram of bodyweight, not as a percentage of calories. When calories fall, the gram target must not fall with them.
- As calories drop, shift toward protein-dense foods — you have to hit the same grams inside a smaller energy budget.
- Keep resistance training going through the loss phase. That is how you preserve the synthesis stimulus while absolute intake is down.
- Track strength with your Big 3 rather than the scale. A scale cannot tell muscle from fat.
How this connects to your Muscle Index
The Muscle Index is bodyweight-adjusted, which makes a cut deceptive: your Big 3 total can stay flat and the score still rises as weight comes off. The inverse is the warning sign — if the score is climbing while your Big 3 falls, you are losing muscle. During a cut, read the raw Big 3 first and the index second.
Muscle loss during weight loss is covered in semaglutide and muscle loss, and the training response in exercise for sarcopenia. Setting a daily protein target is in total intake over timing.
Frequently asked questions
Do GLP-1 weight-loss drugs reduce protein intake?
The proportion is largely maintained — randomised liraglutide trials held protein at roughly 13.9–17.5% of total energy. But because total energy falls, absolute protein in grams can drop, and the decline is larger with more potent appetite suppression.
Is keeping my protein percentage enough?
No. Even with the proportion preserved, falling total energy drags absolute intake down with it, potentially below the level needed to adequately stimulate muscle protein synthesis in older adults. Set the target in grams per kilogram of bodyweight instead.
Why are older adults at greater risk?
Older adults have anabolic resistance, meaning the same protein dose produces a weaker muscle protein synthesis response. Starting from that disadvantage, a further drop in absolute intake compounds the risk. Sarcopenia raises the risk of falls, fractures, disability and mortality.
What is sarcopenic obesity?
It is sarcopenia and obesity occurring together. Type 2 diabetes and obesity frequently coexist with sarcopenia, producing a combination of high body weight with low muscle mass and strength that is clinically difficult to manage.
How do I check whether I am preserving muscle during a cut?
Use strength records rather than the scale. A bodyweight-adjusted score rises as weight comes off, so if that score is climbing while your raw Big 3 total falls, you are losing muscle. During a cut, read the raw lifts first.
Source: Advances in Therapy